Health / Medical Topics

    Syk-JAK Inhibitor PRT062070

    An orally bioavailable dual inhibitor of spleen tyrosine kinase (Syk) and Janus-associated kinases (JAK), with potential anti-inflammatory and antineoplastic activity. Upon oral administration, Syk-JAK inhibitor PRT062070 specifically binds to and inhibits the activity of Syk, JAK1, and JAK3 with preferential inhibition of JAK1 and JAK3-dependent cytokine-mediated signaling and functional responses. This negatively affects the downstream JAK-STAT (signal transducer and activator of transcription) pathway, and leads to both reduced inflammation in various animal models and enhanced antiproliferative activity towards non-Hodgkin's lymphoma (NHL) cell lines. Syk is a non-receptor cytoplasmic tyrosine kinase involved in signal transduction in cells of hematopoietic origin including B cells, macrophages, basophils and neutrophils. Abnormal function of Syk has been implicated in several hematopoietic malignancies including NHL and chronic lymphocytic leukemia (CLL). The JAK-STAT pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies. (NCI Thesaurus)




    YOU MAY ALSO LIKE

    Human SYK wild-type allele is located within 9q22 and is approximately 94 kb in length. This allele, which encodes tyrosine-protein kinase SYK…
    A substance being studied in the treatment of cancer and certain other diseases, such as rheumatoid arthritis. It may block tumor cell…
    This gene plays a role in receptor tyrosine phosphorylation signal transduction, phagocytosis, endothelial cell growth and proliferation.
    The syk family tyrosine kinases are non-receptor protein tyrosine kinases structurally similar to the syk protein (spleen tyrosine kinase) containing two SH2…
    The NCI term type designation for a synonym.
    Marker studies not available or not performed. (AJCC 7th ed.)

    © 1991-2023 The Titi Tudorancea Bulletin | Titi Tudorancea® is a Registered Trademark | Terms of use and privacy policy
    Contact